Skip to content

Study · Animal study (in vivo) · mouse · 2016

17 results

Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice.

Zhang Y, Xu F, Liang H, Cai M, Wen X, Li X, Weng J

Oncology reports8 Dec 2015Cited by 40 (Europe PMC)

PMID26648451 (opens in a new tab)DOI10.3892/or.2015.4476 (opens in a new tab)PepBankPUB-26648451
Source linkPubMedAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In nude mice with Ishikawa xenografts, exenatide slowed tumor growth compared with control.

    In plain wordsIn mice with endometrial cancer tumors, exenatide slowed tumor growth compared with control.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTumor growth rate
    Study

    mousen: not reported in source

    Ishikawa xenografts in nude mice
    Comparator
    control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tumor growth rate in exenatide group was slower than that in control group, and the apoptosis rate of exenatide group was higher than that in control group.
    1 context sentence
    Summary · context
    To investigate whether exenatide promotes or inhibits the growth of endometrial cancer, we used the subcutaneous human endometrial cancer cell Ishikawa xenografts in nude mouse model, and divided them into control group and exenatide-treated group.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In nude mice with Ishikawa xenografts, exenatide increased apoptosis compared with control.

    In plain wordsIn mice with endometrial cancer tumors, exenatide increased tumor cell death by apoptosis compared with control.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseTumor apoptosis rate
    Study

    mousen: not reported in source

    Ishikawa xenografts in nude mice
    Comparator
    control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tumor growth rate in exenatide group was slower than that in control group, and the apoptosis rate of exenatide group was higher than that in control group.
    1 context sentence
    Summary · context
    To investigate whether exenatide promotes or inhibits the growth of endometrial cancer, we used the subcutaneous human endometrial cancer cell Ishikawa xenografts in nude mouse model, and divided them into control group and exenatide-treated group.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In nude mice with Ishikawa xenografts, exenatide increased phosphorylated AMPK protein.

    In plain wordsIn mice with endometrial cancer tumors, exenatide increased phosphorylated AMPK protein.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasePhosphorylated AMPK
    Study

    mousen: not reported in source

    Ishikawa xenografts in nude mice
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was an increase of phosphorylated-AMPK protein, a decrease of phosphorylated-mTOR protein both in vivo and in vitro after exenatide or exendin-4 treatment.
    1 context sentence
    Summary · context
    To investigate whether exenatide promotes or inhibits the growth of endometrial cancer, we used the subcutaneous human endometrial cancer cell Ishikawa xenografts in nude mouse model, and divided them into control group and exenatide-treated group.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In nude mice with Ishikawa xenografts, exenatide reduced phosphorylated mTOR protein.

    In plain wordsIn mice with endometrial cancer tumors, exenatide reduced phosphorylated mTOR protein.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePhosphorylated mTOR
    Study

    mousen: not reported in source

    Ishikawa xenografts in nude mice
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was an increase of phosphorylated-AMPK protein, a decrease of phosphorylated-mTOR protein both in vivo and in vitro after exenatide or exendin-4 treatment.
    1 context sentence
    Summary · context
    To investigate whether exenatide promotes or inhibits the growth of endometrial cancer, we used the subcutaneous human endometrial cancer cell Ishikawa xenografts in nude mouse model, and divided them into control group and exenatide-treated group.
  5. 05LabIn vitro (cells)Efficacy outcome

    In Ishikawa cells, exendin‑4 reduced cell viability.

    In plain wordsIn cells, exendin‑4 reduced endometrial cancer cell viability.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCell viability
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, exendin-4 also attenuated Ishikawa cell viability and clone formation rate, but promoted cell apoptosis.
  6. 06LabIn vitro (cells)Efficacy outcome

    In Ishikawa cells, exendin‑4 reduced clone formation rate.

    In plain wordsIn cells, exendin‑4 reduced endometrial cancer colony formation.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseClone formation rate
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, exendin-4 also attenuated Ishikawa cell viability and clone formation rate, but promoted cell apoptosis.
  7. 07LabIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 increased apoptosis.

    In plain wordsIn cells, exendin‑4 increased endometrial cancer cell death by apoptosis.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCell apoptosis
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, exendin-4 also attenuated Ishikawa cell viability and clone formation rate, but promoted cell apoptosis.
  8. 08LabIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 increased phosphorylated AMPK protein.

    In plain wordsIn cells, exendin‑4 increased phosphorylated AMPK protein.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasePhosphorylated AMPK
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was an increase of phosphorylated-AMPK protein, a decrease of phosphorylated-mTOR protein both in vivo and in vitro after exenatide or exendin-4 treatment.
    1 context sentence
    Summary · context
    In vitro, exendin-4 also attenuated Ishikawa cell viability and clone formation rate, but promoted cell apoptosis.
  9. 09LabIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 reduced phosphorylated mTOR protein.

    In plain wordsIn cells, exendin‑4 reduced phosphorylated mTOR protein.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePhosphorylated mTOR
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was an increase of phosphorylated-AMPK protein, a decrease of phosphorylated-mTOR protein both in vivo and in vitro after exenatide or exendin-4 treatment.
    1 context sentence
    Summary · context
    In vitro, exendin-4 also attenuated Ishikawa cell viability and clone formation rate, but promoted cell apoptosis.

Studies that did not test the peptide alone8

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 10LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 plus AICAR increased apoptosis compared with exendin‑4 alone.

    In plain wordsIn cells, exendin‑4 plus AICAR increased apoptosis compared with exendin‑4 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseApoptosis with AICAR
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Comparator
    exendin-4 alone
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Moreover, when treated with exendin-4 plus AICAR, an AMPK activator, cell apoptosis increased with higher ratio of phosphorylayed-AMPK/AMPK, lower ratio of phosphorylated-mTOR/mTOR and higher expression of cleaved caspase-3 than those in exendin-4 alone group

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 11LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 plus AICAR increased the phosphorylated AMPK/AMPK ratio compared with exendin‑4 alone.

    In plain wordsIn cells, exendin‑4 plus AICAR increased the phosphorylated AMPK/AMPK ratio compared with exendin‑4 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasePhosphorylated AMPK/AMPK with AICAR
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Comparator
    exendin-4 alone
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Moreover, when treated with exendin-4 plus AICAR, an AMPK activator, cell apoptosis increased with higher ratio of phosphorylayed-AMPK/AMPK, lower ratio of phosphorylated-mTOR/mTOR and higher expression of cleaved caspase-3 than those in exendin-4 alone group

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 12LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 plus AICAR reduced the phosphorylated mTOR/mTOR ratio compared with exendin‑4 alone.

    In plain wordsIn cells, exendin‑4 plus AICAR reduced the phosphorylated mTOR/mTOR ratio compared with exendin‑4 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePhosphorylated mTOR/mTOR with AICAR
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Comparator
    exendin-4 alone
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Moreover, when treated with exendin-4 plus AICAR, an AMPK activator, cell apoptosis increased with higher ratio of phosphorylayed-AMPK/AMPK, lower ratio of phosphorylated-mTOR/mTOR and higher expression of cleaved caspase-3 than those in exendin-4 alone group

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 13LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 plus AICAR increased cleaved caspase-3 expression compared with exendin‑4 alone.

    In plain wordsIn cells, exendin‑4 plus AICAR increased cleaved caspase-3 expression compared with exendin‑4 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCleaved caspase-3 with AICAR
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Comparator
    exendin-4 alone
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Moreover, when treated with exendin-4 plus AICAR, an AMPK activator, cell apoptosis increased with higher ratio of phosphorylayed-AMPK/AMPK, lower ratio of phosphorylated-mTOR/mTOR and higher expression of cleaved caspase-3 than those in exendin-4 alone group

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 14LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 plus compound C reduced apoptosis compared with exendin‑4 alone.

    In plain wordsIn cells, exendin‑4 plus compound C reduced apoptosis compared with exendin‑4 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseApoptosis with compound C
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Comparator
    exendin-4 alone
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    and the results were the opposite when treated with exendin-4 plus compound C, an AMPK inhibitor.
    1 context sentence
    Summary · context
    Moreover, when treated with exendin-4 plus AICAR, an AMPK activator, cell apoptosis increased with higher ratio of phosphorylayed-AMPK/AMPK, lower ratio of phosphorylated-mTOR/mTOR and higher expression of cleaved caspase-3 than those in exendin-4 alone group

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  6. 15LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 plus compound C reduced the phosphorylated AMPK/AMPK ratio compared with exendin‑4 alone.

    In plain wordsIn cells, exendin‑4 plus compound C reduced the phosphorylated AMPK/AMPK ratio compared with exendin‑4 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePhosphorylated AMPK/AMPK with compound C
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Comparator
    exendin-4 alone
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    and the results were the opposite when treated with exendin-4 plus compound C, an AMPK inhibitor.
    1 context sentence
    Summary · context
    Moreover, when treated with exendin-4 plus AICAR, an AMPK activator, cell apoptosis increased with higher ratio of phosphorylayed-AMPK/AMPK, lower ratio of phosphorylated-mTOR/mTOR and higher expression of cleaved caspase-3 than those in exendin-4 alone group

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  7. 16LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 plus compound C increased the phosphorylated mTOR/mTOR ratio compared with exendin‑4 alone.

    In plain wordsIn cells, exendin‑4 plus compound C increased the phosphorylated mTOR/mTOR ratio compared with exendin‑4 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasePhosphorylated mTOR/mTOR with compound C
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Comparator
    exendin-4 alone
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    and the results were the opposite when treated with exendin-4 plus compound C, an AMPK inhibitor.
    1 context sentence
    Summary · context
    Moreover, when treated with exendin-4 plus AICAR, an AMPK activator, cell apoptosis increased with higher ratio of phosphorylayed-AMPK/AMPK, lower ratio of phosphorylated-mTOR/mTOR and higher expression of cleaved caspase-3 than those in exendin-4 alone group

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  8. 17LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In Ishikawa cells, exendin‑4 plus compound C reduced cleaved caspase-3 expression compared with exendin‑4 alone.

    In plain wordsIn cells, exendin‑4 plus compound C reduced cleaved caspase-3 expression compared with exendin‑4 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCleaved caspase-3 with compound C
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Comparator
    exendin-4 alone
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    and the results were the opposite when treated with exendin-4 plus compound C, an AMPK inhibitor.
    1 context sentence
    Summary · context
    Moreover, when treated with exendin-4 plus AICAR, an AMPK activator, cell apoptosis increased with higher ratio of phosphorylayed-AMPK/AMPK, lower ratio of phosphorylated-mTOR/mTOR and higher expression of cleaved caspase-3 than those in exendin-4 alone group

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.